Literature DB >> 25288081

Abdominal candidiasis is a hidden reservoir of echinocandin resistance.

Ryan K Shields1, M Hong Nguyen2, Ellen G Press3, Cornelius J Clancy4.   

Abstract

FKS mutant Candida isolates were recovered from 24% (6/25) of abdominal candidiasis patients exposed to echinocandin. Candida glabrata (29%) and Candida albicans (14%) mutants were identified. Multidrug-resistant bacteria were recovered from 83% of FKS mutant infections. Mutations were associated with prolonged echinocandin exposure (P = 0.01), breakthrough infections (P = 0.03), and therapeutic failures despite source control interventions (100%). Abdominal candidiasis is a hidden reservoir for the emergence of echinocandin-resistant Candida.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25288081      PMCID： PMC4249510          DOI： 10.1128/AAC.04134-14

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  18 in total

1.  Treatment of candidal cholangitis with caspofungin therapy in a patient with a liver transplant: documentation of biliary excretion of caspofungin.

Authors:  Miguel Goicoechea; Joshua Fierer; Scott Johns
Journal:  Clin Infect Dis       Date:  2004-04-01       Impact factor: 9.079

Review 2.  Candida peritonitis: an update on the latest research and treatments.

Authors:  Herman Anthony Carneiro; Anastasios Mavrakis; Eleftherios Mylonakis
Journal:  World J Surg       Date:  2011-12       Impact factor: 3.352

Review 3.  Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria.

Authors:  Brahm H Segal; Raoul Herbrecht; David A Stevens; Luis Ostrosky-Zeichner; Jack Sobel; Claudio Viscoli; Thomas J Walsh; Johan Maertens; Thomas F Patterson; John R Perfect; Bertrand Dupont; John R Wingard; Thierry Calandra; Carol A Kauffman; John R Graybill; Lindsey R Baden; Peter G Pappas; John E Bennett; Dimitrios P Kontoyiannis; Catherine Cordonnier; Maria Anna Viviani; Jacques Bille; Nikolaos G Almyroudis; L Joseph Wheat; Wolfgang Graninger; Eric J Bow; Steven M Holland; Bart-Jan Kullberg; William E Dismukes; Ben E De Pauw
Journal:  Clin Infect Dis       Date:  2008-09-01       Impact factor: 9.079

4.  Pharmacodynamics of caspofungin in a murine model of systemic candidiasis: importance of persistence of caspofungin in tissues to understanding drug activity.

Authors:  Arnold Louie; Mark Deziel; Weiguo Liu; Michael F Drusano; Tawanda Gumbo; George L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

5.  Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance.

Authors:  A-P Magiorakos; A Srinivasan; R B Carey; Y Carmeli; M E Falagas; C G Giske; S Harbarth; J F Hindler; G Kahlmeter; B Olsson-Liljequist; D L Paterson; L B Rice; J Stelling; M J Struelens; A Vatopoulos; J T Weber; D L Monnet
Journal:  Clin Microbiol Infect       Date:  2011-07-27       Impact factor: 8.067

6.  Distribution of micafungin in the tissue fluids of patients with invasive fungal infections.

Authors:  Noriaki Yamada; Keisuke Kumada; Satoshi Kishino; Nobuo Mochizuki; Keiko Ohno; Shinji Ogura
Journal:  J Infect Chemother       Date:  2011-05-03       Impact factor: 2.211

7.  Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials.

Authors:  David R Andes; Nasia Safdar; John W Baddley; Geoffrey Playford; Annette C Reboli; John H Rex; Jack D Sobel; Peter G Pappas; Bart Jan Kullberg
Journal:  Clin Infect Dis       Date:  2012-03-12       Impact factor: 9.079

8.  In vitro susceptibility of breakthrough Candida bloodstream isolates correlates with daily and cumulative doses of fluconazole.

Authors:  Cornelius J Clancy; Benjamin Staley; M Hong Nguyen
Journal:  Antimicrob Agents Chemother       Date:  2006-10       Impact factor: 5.191

9.  The presence of an FKS mutation rather than MIC is an independent risk factor for failure of echinocandin therapy among patients with invasive candidiasis due to Candida glabrata.

Authors:  Ryan K Shields; M Hong Nguyen; Ellen G Press; Andrea L Kwa; Shaoji Cheng; Chen Du; Cornelius J Clancy
Journal:  Antimicrob Agents Chemother       Date:  2012-07-02       Impact factor: 5.191

10.  Disposition of caspofungin, a novel antifungal agent, in mice, rats, rabbits, and monkeys.

Authors:  Punam Sandhu; Xin Xu; Peter J Bondiskey; Suresh K Balani; Michael L Morris; Yui S Tang; Alisha R Miller; Paul G Pearson
Journal:  Antimicrob Agents Chemother       Date:  2004-04       Impact factor: 5.191
View more
  39 in total

Review 1.  [Resistant fungi].

Authors:  M J G T Vehreschild; O A Cornely
Journal:  Internist (Berl)       Date:  2015-11       Impact factor: 0.743

2.  Mutant Prevention Concentration and Mutant Selection Window of Micafungin and Anidulafungin in Clinical Candida glabrata Isolates.

Authors:  Pilar Escribano; Jesús Guinea; María Ángeles Bordallo-Cardona; Laura Judith Marcos-Zambrano; Carlos Sánchez-Carrillo; Elia Gómez G de la Pedrosa; Rafael Cantón; Emilio Bouza
Journal:  Antimicrob Agents Chemother       Date:  2018-02-23       Impact factor: 5.191

Review 3.  Essentials in Candida bloodstream infection.

Authors:  Sibylle C Mellinghoff; O A Cornely; N Jung
Journal:  Infection       Date:  2018-09-14       Impact factor: 3.553

4.  Penetration of Ibrexafungerp (Formerly SCY-078) at the Site of Infection in an Intra-abdominal Candidiasis Mouse Model.

Authors:  Annie Lee; Brendan Prideaux; Matthew Zimmerman; Claire Carter; Stephen Barat; David Angulo; Véronique Dartois; David S Perlin; Yanan Zhao
Journal:  Antimicrob Agents Chemother       Date:  2020-02-21       Impact factor: 5.191

Review 5.  Beyond tissue concentrations: antifungal penetration at the site of infection.

Authors:  Yanan Zhao; Brendan Prideaux; Shane Baistrocchi; Donald C Sheppard; David S Perlin
Journal:  Med Mycol       Date:  2019-04-01       Impact factor: 4.076

6.  Rate of FKS Mutations among Consecutive Candida Isolates Causing Bloodstream Infection.

Authors:  Ryan K Shields; M Hong Nguyen; Ellen G Press; Richard Cumbie; Eileen Driscoll; A William Pasculle; Cornelius J Clancy
Journal:  Antimicrob Agents Chemother       Date:  2015-09-21       Impact factor: 5.191

7.  In Vitro Exposure to Increasing Micafungin Concentrations Easily Promotes Echinocandin Resistance in Candida glabrata Isolates.

Authors:  María Ángeles Bordallo-Cardona; Pilar Escribano; Elia Gómez G de la Pedrosa; Laura Judith Marcos-Zambrano; Rafael Cantón; Emilio Bouza; Jesús Guinea
Journal:  Antimicrob Agents Chemother       Date:  2017-01-24       Impact factor: 5.191

Review 8.  What has changed in the treatment of invasive candidiasis? A look at the past 10 years and ahead.

Authors:  Matteo Bassetti; Elda Righi; Philippe Montravers; Oliver A Cornely
Journal:  J Antimicrob Chemother       Date:  2018-01-01       Impact factor: 5.790

9.  Multicenter Study of Method-Dependent Epidemiological Cutoff Values for Detection of Resistance in Candida spp. and Aspergillus spp. to Amphotericin B and Echinocandins for the Etest Agar Diffusion Method.

Authors:  A Espinel-Ingroff; M Arendrup; E Cantón; S Cordoba; E Dannaoui; J García-Rodríguez; G M Gonzalez; N P Govender; E Martin-Mazuelos; M Lackner; C Lass-Flörl; M J Linares Sicilia; M A Rodriguez-Iglesias; T Pelaez; R K Shields; G Garcia-Effron; J Guinea; M Sanguinetti; J Turnidge
Journal:  Antimicrob Agents Chemother       Date:  2016-12-27       Impact factor: 5.191

10.  Multicenter study of epidemiological cutoff values and detection of resistance in Candida spp. to anidulafungin, caspofungin, and micafungin using the Sensititre YeastOne colorimetric method.

Authors:  A Espinel-Ingroff; M Alvarez-Fernandez; E Cantón; P L Carver; S C-A Chen; G Eschenauer; D L Getsinger; G M Gonzalez; N P Govender; A Grancini; K E Hanson; S E Kidd; K Klinker; C J Kubin; J V Kus; S R Lockhart; J Meletiadis; A J Morris; T Pelaez; G Quindós; M Rodriguez-Iglesias; F Sánchez-Reus; S Shoham; N L Wengenack; N Borrell Solé; J Echeverria; J Esperalba; E Gómez-G de la Pedrosa; I García García; M J Linares; F Marco; P Merino; J Pemán; L Pérez Del Molino; E Roselló Mayans; C Rubio Calvo; M Ruiz Pérez de Pipaon; G Yagüe; G Garcia-Effron; J Guinea; D S Perlin; M Sanguinetti; R Shields; J Turnidge
Journal:  Antimicrob Agents Chemother       Date:  2015-08-17       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.